SAM
KPTI icon

Silverback Asset Management’s Karyopharm Therapeutics KPTI Stock Holding History

Silverback Asset Management’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$977K Hold
100,000
– – 0.11% 57
2026
Q1 		$557K Buy
+100,000
New +$762K 0.08% 56

Other funds holding KPTI

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CCM
Catalio Capital Management New York $532M AUM 171.17% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Silverback Asset Management's KPTI Position: Q2 2026 in Review

Silverback Asset Management reduced its Karyopharm Therapeutics (KPTI) stake by 54% in Q2 2026, selling an estimated $304K and leaving 30,000 shares worth $293K. The position accounts for 0.03% of the portfolio, ranked #64.

Silverback Asset Management first reported a position in KPTI in Q2 2025 and has held it in 5 quarters since. The position peaked at $362K in Q1 2026. 96 funds tracked by Wall St. Rank hold KPTI as of Q2 2026.

  • Silverback Asset Management held 30,000 shares of Karyopharm Therapeutics worth $293K as of Q2 2026.
  • Silverback Asset Management sold 35,000 Karyopharm Therapeutics shares in Q2 2026, an estimated $304K.
  • Karyopharm Therapeutics made up 0.03% of Silverback Asset Management's portfolio in Q2 2026, its #64 holding.
  • Silverback Asset Management first reported a position in Karyopharm Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Silverback Asset Management's Karyopharm Therapeutics position peaked at $362K in Q1 2026.
  • 96 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2026.

Based on Silverback Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.